Operational transplant acceptance induced by mesenchymal stem cells - beyond early effects of donor antigen

免疫调节性间充质干细胞(MSC)治疗是一种补充标准药物治疗的新方法，以实现对实体器官移植的接受。在我们以前的工作中，我们已经描述了这种致耐受干细胞效应的许多特征，包括细胞输注的剂量、途径和时机，供体抗原和抗原提呈细胞在这一过程中的作用，同时免疫抑制的必要性，耐受的可转移性，中间细胞类型的出现和调节细胞的产生。这项建议中建议的实验将阐明MSC对髓系来源的抑制细胞的影响，该细胞控制Th17型和T调节性T细胞之间的平衡。

Immunomodulatory mesenchymal stem cell (MSC) therapy is a novel approach to complement standard pharmacotherapy to achieve the acceptance of solid organ allografts. In our previous work we have described a multitude of features of such tolerogenic stem cell effects, including the dose, route and timing of cell infusions, the role of donor antigen and antigen presenting cells in the process, the necessity of concurrent immunosuppression, the transferability of tolerance, the emergence of intermediate cell types and the generation of regulatory cells. Experiments suggested in this proposal will clarify the influence that MSC have on myeloid derived suppressor cells which govern the balance between Th17-type and T regulatory T cells.